Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor

Phase 2

Terminated

Conditions: Lung Neoplasms

Interventions: Drug: Pemetrexed
Drug: carboplatin
Drug: gemcitabine

First Posted Date: 2006-07-26

Last Posted Date: 2010-08-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 41

Registration Number: NCT00356525

Locations: 🇮🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India

Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Human Insulin Inhalation Powder
Drug: Insulin Glargine

First Posted Date: 2006-07-25

Last Posted Date: 2019-09-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 555

Registration Number: NCT00355849

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event

Phase 2

Completed

Conditions: Coronary Arteriosclerosis
Acute Coronary Syndrome

Interventions: Drug: prasugrel 10 mg
Drug: clopidogrel
Drug: prasugrel placebo
Drug: prasugrel 60 mg
Drug: clopidogrel placebo

First Posted Date: 2006-07-25

Last Posted Date: 2010-11-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 139

Registration Number: NCT00356135

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Houston, Texas, United States

Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Human Insulin Inhalation Powder
Drug: Injectable insulin
Drug: Insulin Glargine

First Posted Date: 2006-07-25

Last Posted Date: 2018-03-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 494

Registration Number: NCT00356109

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toa Baja, Puerto Rico

Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short Stature

Phase 3

Completed

Conditions: Idiopathic Short Stature (ISS)

Interventions: Drug: somatropin
Drug: leuprorelin

First Posted Date: 2006-07-20

Last Posted Date: 2019-09-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 91

Registration Number: NCT00355030

Locations: 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands

Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: carboplatin

First Posted Date: 2006-07-11

Last Posted Date: 2010-10-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 62

Registration Number: NCT00350792

Locations: 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vandoeuvre Les Nancy, France

A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Cetuximab
Biological: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2006-06-22

Last Posted Date: 2011-06-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 121

Registration Number: NCT00343291

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tacoma, Washington, United States

Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

Phase 3

Completed

Conditions: Back Pain
Spinal Fracture
Osteoporosis, Postmenopausal

Interventions: Drug: teriparatide
Drug: risedronate
Drug: placebo

First Posted Date: 2006-06-22

Last Posted Date: 2011-05-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 712

Registration Number: NCT00343252

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorder

Interventions: Drug: olanzapine
Drug: risperidone

First Posted Date: 2006-06-16

Last Posted Date: 2010-02-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 628

Registration Number: NCT00337662

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation

Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: gemcitabine
Drug: paclitaxel

First Posted Date: 2006-06-08

Last Posted Date: 2010-03-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 62

Registration Number: NCT00334802

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy